Financials data is unavailable for this security.
View more
Year on year Ucb SA 's revenues fell -4.80% from 5.52bn to 5.25bn. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 418.00m to 343.00m, a -17.94% decrease.
| Gross margin | 67.80% |
|---|---|
| Net profit margin | 4.40% |
| Operating margin | 8.20% |
| Return on assets | 1.55% |
|---|---|
| Return on equity | 2.67% |
| Return on investment | 1.88% |
More ▼
Cash flow in EURView more
In 2023, Ucb SA did not generate a significant amount of cash. However, the company earned 761.00m from its operations for a Cash Flow Margin of 14.49%. In addition the company used 440.00m on investing activities and also paid 308.00m in financing cash flows.
| Cash flow per share | 4.78 |
|---|---|
| Price/Cash flow per share | 38.40 |
| Book value per share | 47.19 |
|---|---|
| Tangible book value per share | -2.95 |
More ▼
Balance sheet in EURView more
| Current ratio | 1.19 |
|---|---|
| Quick ratio | 0.7806 |
| Total debt/total equity | 0.3394 |
|---|---|
| Total debt/total capital | 0.2534 |
More ▼
Growth rates in EUR
Year on year, growth in dividends per share increased 2.26% while earnings per share excluding extraordinary items fell by -18.48%. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 1.11% |
|---|---|
| Div growth rate (5 year) | 2.36% |
| Payout ratio (TTM) | 105.00% |
| EPS growth(5 years) | -16.00 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -27.96 |
More ▼
